High-dose thiotepa, busulfan, cyclophosphamide and autologous stem cell transplantation as upfront consolidation for systemic non-Hodgkin lymphoma with synchronous central nervous system involvement

Conclusion CNS-directed high-dose chemotherapy and ASCT provides durable remission for patients with synchronous aggressive lymphoma and should be strongly considered as consolidative therapy for eligible patients with systemic NHL with CNS involvement in CR1. Teaser Systemic non-Hodgkin lymphoma with synchronous central nervous system (CNS) involvement traditionally carries a poor prognosis. We found encouraging results with the use of high-dose chemotherapy and autologous stem cell transplantation as consolidation for patients in first complete remission. CNS-directed conditioning with a thiotepa-based regimen might reduce the incidence of relapse and improve the outcomes in this population.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research